Skip to main content
Log in

Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension

A double-blind, randomized study

  • Poster Presentation
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The renal, metabolic and antihypertensive effects of enalapril (E) and slow-release verapamil (V) were compared in a 2-month double-blind crossover trial in 22 patients with newly discovered essential hypertension. The glomerular filtration rate and renal vascular resistance were unaltered; renal blood flow was slightly decreased by V. Serum Ca2+ increased and Na+ excretion declined after V. Serum lipids, glucose, and erythrocyte electrolytes were unchanged. Blood pressure (BP) was lower with E after half the maximum dosage compared with V, but similar BP reductions were obtained after 2 months with the maximum dosage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fagher, B., Henningsen, N., Hulthén, L. et al. Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. Eur J Clin Pharmacol 39 (Suppl 1), S41–S43 (1990). https://doi.org/10.1007/BF03216275

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03216275

Key words

Navigation